ClinicalTrials.gg

Program

abemaciclib

Also written as “Abemaciclib”, “LY2835219” and “Abemaciclib Tablet (Test Formulation)”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Neoplasm Metastasis · Sarcoma, Ewing, led by 2 companies.

Furthest: phase 4, since Jun 12, 201949 company-led studies, 14 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly4814 open or runningphase 4since Jun 12, 2019Jul 12, 2011Nov 2026phase 1 · NCT07818967
Hoffmann-La Roche10 open or runningphase 2since Sep 11, 2017Sep 11, 2017none ahead

Also a collaborator on its studies: Bayer and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Jul 12, 2011.

  1. Jun 12, 2019Phase 4 study in Breast NeoplasmsEli Lilly · NCT03988114 · United States, Argentina, Austria and more
  2. Jul 23, 2019Phase 4 study in Breast NeoplasmsEli Lilly · NCT04031885 · 4 enrolled · United States, Puerto Rico
  3. Aug 26, 2019Phase 1 study in Advanced CancerEli Lilly · NCT04071262 · 6 enrolled · Japan
  4. Jan 22, 2020Phase 2 study in Sarcoma, EwingEli Lilly · NCT04238819 · 47 enrolled · United States, Australia, Belgium and more
  5. May 28, 2020Phase 2 study in Metastatic Castration-Resistant Prostate CancerEli Lilly · NCT04408924 · 44 enrolled · United States, France, Spain
  6. Jan 12, 2021Phase 4 study in Breast NeoplasmsEli Lilly · NCT04707196 · 200 enrolled · India
  7. Feb 11, 2021Phase 3 study in Breast NeoplasmsEli Lilly · NCT04752332 · 111 enrolled · United States, Argentina, Australia and more
  8. Dec 22, 2021Phase 3 study in Breast NeoplasmsEli Lilly · NCT05169567 · 368 enrolled · United States, Argentina, Belgium and more
  9. Mar 10, 2022Phase 3 study in Prostatic NeoplasmsEli Lilly · NCT05288166 · 925 enrolled · United States, Argentina, Australia and more
  10. Jun 28, 2022Phase 2 study in Sarcoma, EwingEli Lilly · NCT05440786 · 46 enrolled · United States, Australia, France and more
  11. Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
  12. Aug 14, 2023Phase 1 study in Prostatic NeoplasmsEli Lilly · NCT05999968 · 10 enrolled · United States, Germany, Spain
  13. May 9, 2024Phase 2 study in GliomaEli Lilly · NCT06413706 · 45 enrolled · United States, Australia, Belgium and more
  14. Aug 26, 2026Phase 1 study in Healthy VolunteersEli Lilly · NCT07818967 · 15 planned · Singapore

Ahead

  1. Nov 2026Primary completion: phase 1 study in Healthy VolunteersEli Lilly · NCT07818967
  2. Feb 2027Primary completion: phase 2 study in GliomaEli Lilly · NCT06413706
  3. May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994

TargetBeta

CDK4 →CDK6 →read by rule
“The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
culmerciclibSino Biopharmaceuticalphase 311
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23

Studies

All 49 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07818967Healthy Volunteers · Singapore1RecruitingEli LillyNov 202615
NCT06413706Glioma · United States, Australia, Belgium and more2Active, not recruitingEli LillyFeb 202745
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingEli LillyMay 2027105
NCT05999968Prostatic Neoplasms · United States, Germany, Spain1TerminatedEli LillyFeb 23, 202410
NCT05440786Sarcoma, Ewing · United States, Australia, France and more2Active, not recruitingEli LillyJan 15, 202546
NCT05288166Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingEli LillyFeb 15, 2024925
NCT05169567Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingEli LillyFeb 8, 2024368
NCT04752332Breast Neoplasms · United States, Argentina, Australia and more3TerminatedEli LillyJun 26, 2024111
NCT04707196Breast Neoplasms · India4CompletedEli LillyJan 9, 2023200
NCT04408924Metastatic Castration-Resistant Prostate Cancer · United States, France, Spain2CompletedEli LillyApr 27, 202244
NCT04238819Sarcoma, Ewing · United States, Australia, Belgium and more2CompletedEli LillyMar 15, 202447
NCT04071262Advanced Cancer · Japan1CompletedEli LillyFeb 12, 20216
NCT04031885Breast Neoplasms · United States, Puerto Rico4TerminatedEli LillyAug 11, 20204
NCT03988114Breast Neoplasms · United States, Argentina, Austria and more4WithdrawnEli LillyMar 23, 20220
NCT03703466Breast Neoplasms · Australia, Belgium, Russian Federation and more2CompletedEli LillyJul 29, 201972
NCT03706365Prostatic Neoplasms · United States, Australia, China and more3Active, not recruitingEli LillyJan 2, 2024393
NCT03280563Breast Neoplasms · United States, Israel, South Korea2CompletedHoffmann-La RocheSep 26, 2024144
NCT03155997Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingEli LillyMar 16, 20205,637
NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more2CompletedEli LillyApr 20, 2018106
NCT02919696Neoplasm Metastasis · China1CompletedEli LillyNov 23, 201826
NCT02884089Healthy · United States1CompletedEli LillyDec 201640
NCT02779751Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more1Active, not recruitingEli LillyFeb 3, 2020100
NCT02763566Breast Neoplasms · Brazil, China, India and more3Active, not recruitingEli LillyMar 29, 2019463
NCT02747004Breast Neoplasms · United States, Argentina, Austria and more2CompletedEli LillyJun 15, 2018234
NCT02745769Colorectal Neoplasms · United States, France, United Kingdom1CompletedEli LillyNov 5, 201823
NCT02688088Neoplasm Metastasis · United States1CompletedEli LillyFeb 4, 201848
NCT02677844Healthy · United States1CompletedEli LillyJul 201635
NCT02675231Hormone Receptor Positive Breast Cancer · United States, Argentina, Australia and more2CompletedEli LillyApr 8, 2019237
NCT02672423Healthy · United States1CompletedEli LillyOct 2016127
NCT02482935Healthy · United States1CompletedEli LillySep 201530
NCT02450539Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2CompletedEli LillyMar 31, 2017159
NCT02441946Breast Neoplasms · United States, Austria, Belgium and more2CompletedEli LillyAug 16, 2016224
NCT02411591Carcinoma, Non-Small-Cell Lung · Belgium, France, Spain1CompletedEli LillyJun 23, 201766
NCT02387814Hepatic Insufficiency · United States1CompletedEli LillyAug 201535
NCT02327143Healthy Volunteers · United Kingdom1CompletedEli LillyFeb 201511
NCT02308020Breast Neoplasms · United States, Australia, Austria and more2CompletedEli LillyNov 8, 2018162
NCT02256267Healthy Volunteers · United States1CompletedEli LillyNov 201424
NCT02246621Breast Neoplasms · United States, Australia, Austria and more3Active, not recruitingEli LillyJan 31, 2017493
NCT02152631Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3Active, not recruitingEli LillySep 15, 2017453
NCT02117648Neoplasms · United States1CompletedEli LillyFeb 201526
NCT02107703Breast Neoplasms · United States, Australia, Belgium and more3Active, not recruitingEli LillyFeb 14, 2017669
NCT02102490Breast Neoplasms · United States, Belgium, France and more2CompletedEli LillyApr 30, 2016132
NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain1CompletedEli LillyMay 2, 2018142
NCT02059148Healthy Volunteers · United States1CompletedEli LillyAug 201424
NCT02057133Breast Neoplasms · United States1Active, not recruitingEli LillyMar 15, 2021198
NCT02014129Neoplasm Metastasis · Japan1CompletedEli LillyApr 1, 201512
NCT01913314Healthy Volunteers · United States1CompletedEli LillyOct 20136
NCT01739309Lymphoma, Mantle-Cell · France, Germany2CompletedEli LillySep 28, 201528
NCT01394016Advanced Cancer · United States1CompletedEli LillyMay 29, 2014225

How it is read

Names in the registry

  • “Abemaciclib”, 41 entries
  • “LY2835219”, 5 entries
  • “Abemaciclib Tablet (Test Formulation)”, 2 entries
  • “Abemaciclib Tablet (Reference Formulation)”, 1 entry
  • “Abemaciclib Oral Granules (Test Formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.